A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Unknown Primary	NCT ID:	NCT06588478
Trial Phases:	Phase II	Protocol IDs:	18877 (primary) NCI-2025-02626 2024-515689-15-00 J2N-MC-JZNX
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Loxo Oncology, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06588478

Summary

The main purpose of this study is to assess the efficacy and safety of 3 dose levels of
Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment
including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to
last approximately 3 years.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.